If your institution subscribes to this resource, and you don't have a MyAccess Profile, please contact your library's reference desk for information on how to gain access to this resource from off-campus.
Antineoplastic, epidermal growth factor receptor (EGFR) family kinase inhibitor
EGFR-positive (exon 19 deletion or exon 21 L858R substitutions) non-small cell lung cancer (NSCLC)†
Afatinib, gefitinib, erlotinib, osimertinib
Chapter 67. Pathway-Targeted Therapies: Monoclonal Antibodies, Protein Kinase Inhibitors, and Various Small Molecules > Inhibitors of Epidermal Growth Factor Receptor (EGFR) Function
eChapter 2018: The Goodman & Gilman Year in Review New and Noteworthy FDA Approvals